Skip to main content

ADVERTISEMENT

cost-effectiveness

Conference Coverage
12/09/2020
Journal of Clinical Pathways
Conference Coverage
12/05/2020
Journal of Clinical Pathways
News
08/07/2020
Nivolumab plus ipilimumab and pembrolizumab are the most cost-effective front-line treatment options for patients with newly diagnosed advanced melanoma and unknown BRAF status, according to a study published in JAMA...
Nivolumab plus ipilimumab and pembrolizumab are the most cost-effective front-line treatment options for patients with newly diagnosed advanced melanoma and unknown BRAF status, according to a study published in JAMA...
...
08/07/2020
Journal of Clinical Pathways
Introduction: The Medicare Access and CHIP Reauthorization Act (MACRA) changes clinician reimbursement from a fee-for-service payment system to a fee-for-value system. Physicians are scor...
02/09/2019
Background: With diabetes considered a major global health problem, its rising prevalence will affect worldwide populations without regard for geographic location. Concerns are fuele...
02/09/2019